Celyad Oncology (CYAD) Surges 138% and Reaches Five-Month High
Celyad Oncology (CYAD), an oncology biotech company, surged 138% for the day, reaching a new five-month high. It is unclear why the Company soared today, as there were no news on or for the company.
The Company’s latest press release is from around a month ago, when they announced a strategic shift to their preclinical stage pipeline, and pulled the plug on their only human trial asset. They will provide their next update in Q2 of 2023.
CYAD is a member of the PRISM Gene Therapy Index, which jumped 3.5% alongside PRISM Solar for the best performing index of the day. Of course, the Gene Therapy Index received a large boost from CYAD.
About Celyad Oncology
Celyad Oncology is a biotechnology company focused on the discovery and development of innovative technologies chimeric antigen receptor (CAR) T-cell therapies. The Company is focusing on opportunities to fully harness the true potential of its proprietary technology platforms and intellectual property and support the development of next-generation CAR T candidates in solid tumors and hematological malignancies. Celyad Oncology is based in Mont-Saint-Guibert, Belgium and New York, NY. For more information, please visit www.celyad.com.
